DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seven brokerages give DBV Technologies an average “Moderate Buy” rating, with a consensus 12-month price target of $48.50 versus a recent price of $14.97.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 71.74% of the company, while several firms recently initiated or increased positions.
• Recent results fell short of expectations: DBV reported a quarterly loss of $0.60 per share versus the consensus loss estimate of $0.12, alongside revenue of $0.70 million below the $0.90 million forecast.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $48.50.

Several research firms have commented on DBVT. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Friday, May 1st. Weiss Ratings downgraded shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 17th. HC Wainwright restated a "buy" rating on shares of DBV Technologies in a report on Tuesday, June 30th. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 30th. Finally, Guggenheim reiterated a "buy" rating and set a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Allworth Financial LP purchased a new stake in shares of DBV Technologies in the fourth quarter worth approximately $32,000. Royal Bank of Canada purchased a new position in DBV Technologies during the 4th quarter valued at $34,000. Truvestments Capital LLC grew its position in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock valued at $75,000 after acquiring an additional 1,620 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in DBV Technologies in the 4th quarter valued at $115,000. Finally, Two Sigma Investments LP bought a new position in DBV Technologies in the 3rd quarter valued at $167,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $14.97 on Wednesday. The firm has a market capitalization of $941.31 million, a price-to-earnings ratio of -4.26 and a beta of -0.93. The business has a 50 day simple moving average of $14.91 and a 200-day simple moving average of $18.29. DBV Technologies has a 1 year low of $8.70 and a 1 year high of $26.18.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, analysts expect that DBV Technologies will post -2.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source